Stock Financial Ratios

BIO / Bio-Rad Laboratories, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price245.62
Volume178,600.00
Market Cap ($M)7,368.84
Enterprise Value ($M)7,446.14
Book Value ($M)2,490.50
Book Value / Share84.69
Price / Book2.82
NCAV ($M)556.55
NCAV / Share116.90
Price / NCAV9.07
Income Statement (mra) ($M)
Revenue2,019.44
EBITDA166.71
Net Income113.10
Balance Sheet (mrq) ($M)
Cash & Equivalents418.65
Cash / Share14.24
Assets3,874.64
Liabilities1,221.04
Quick Ratio2.92
Current Ratio4.03
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.03
Return on Equity (ROE)0.04
Identifiers and Descriptors
CUSIP090572207
Central Index Key (CIK)12208
Industry Groups
SIC 3826 - Laboratory Analytical Instruments
Other Related CUSIPS
090572957
090572907
Share Statistics
Common Shares Outstanding24,236,681
Common Shares Outstanding25,125,441
Weighted Average Number Of Diluted Shares Outstanding29,409,000
Weighted Average Number Of Shares Outstanding Basic29,186,000
Preferred Stock Shares Outstanding0
Scoring Models
Piotroski F-Score7.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Other Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Debt Per Share14.83
Assets Current Per Share61.40
Cash And Equivalents Per Share14.24
Inventory Raw Materials Per Share3.87
Liabilities Current Per Share0.00
Assets Per Share131.75
Minority Interest Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Property Plant And Equipment Per Share0.00
Liabilities Per Share41.52
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Retained Earnings Per Share62.51
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share18.41
Liabilities And Stock Equity Per Share0.00
Cash Per Share14.24
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Net Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Inventory Finished Goods Per Share10.20
Treasury Stock Per Share0.00
Accounts Receivable Per Share12.45
Equity Per Share88.90
Goodwill Per Share17.18
Intangibles Per Share7.84

Related News Stories

Henry Schein (HSIC) Q4 Earnings in Line, 2018 View Upbeat

2018-02-20 zacks
Henry Schein, Inc. (HSIC - Free Report) reported adjusted earnings per share (EPS) of 97 cents in the fourth quarter of 2017, up 3.2% year over year. Adjusted EPS remained in line with the Zacks Consensus Estimate. The year-over-year upside in earnings was driven by strong revenue growth across all the business segments. (16-0)

Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

2018-02-20 zacks
IDEXX Laboratories, Inc. (IDXX - Free Report) has been gaining investor confidence on consistently positive results. The stock has rallied 28.1% over the last year, ahead of the S&P 500’s 16% gain and the broader industry’s 24% rise. (16-0)

Myriad Genetics Banks on Product Launches, Competition Rife

2018-02-19 zacks
On Feb 16, we issued an updated research report on Myriad Genetics, Inc. (MYGN - Free Report) . The stock carries a Zacks Rank #3 (Hold). (37-0)

Abiomed Hits New 52-Week High: 4 Factors Driving the Stock

2018-02-19 zacks
Abiomed, Inc. (ABMD - Free Report) scaled a new 52-week high of $268.72 on Feb 16, eventually closing a bit lower at $267.74. The company’s shares have gained 74.6% in the last six months, compared with the broader industry’s 14.6% gain. (59-0)

Edwards Lifesciences' CE Mark for CENTERA Boosts THVT Arm

2018-02-16 zacks
Edwards Lifesciences Corporation (EW - Free Report) announced the receipt of CE Mark for its self-expanding CENTERA valve. The valve is used for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery. However, the CENTERA valve is not approved for commercial sale in the United States. (11-0)

CUSIP: 090572207